


(A),

within the range from about 200 to about 1600 mg/day.

15. The pharmaceutical product according to claim 14, wherein the compound of formula (I) is the compound 4-{[(2R,3S,4R,5S)-3-(3-Chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid 1-mPEG-carbonyloxy-ethyl ester (mPEG, average MW, ~2000).

16. The pharmaceutical product according to claim 14, wherein the compound of formula (I) is the compound 4-{[(2R,3S,4R,5S)-3-(3-Chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid 1-mPEG-carbonyloxy-ethyl ester (mPEG, average MW, ~2200).

17. The pharmaceutical product according to any one of claims 14 to 16, wherein the compound of formula (I) is administered on days 1 to 5, followed by a 23 days rest perior of a 28 days treatment cycle.

18. The pharmaceutical product according to claim 17, wherein the compoud of formula (I) is administered once daily (qd) or two times a day (BID).

19. The pharmaceutical product according to any one of claims 14 to 18, wherein the cancer is Acute Myeloid Leukemia (AML).

~~20. The novel products, methods and uses substantially as described herein.~~